• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Cullinan Therapeutics (CGEM)

Common Shares
Sell: $6.42|Buy: $10.10|Change: 0.24 (2.90%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Address




Website

https://cullinantherapeutics.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Cullinan Therapeutics Inc Fourth Quarter Earnings Results for 20252026-02-27T00:00:00
Cullinan Therapeutics Inc Annual Report for 20252026-02-27T00:00:00
Cullinan Therapeutics Inc Third Quarter Earnings Results for 20252025-11-07T00:00:00
Cullinan Therapeutics Inc Second Quarter Earnings Results for 20252025-08-08T00:00:00
Cullinan Therapeutics Inc Annual General Meeting for 20252025-06-26T10:00:00
Cullinan Therapeutics Inc First Quarter Earnings Results for 20252025-05-15T00:00:00

Previous key dates

NameKey Date
Cullinan Therapeutics Inc First Quarter Earnings Results for 20252025-05-15T00:00:00
Leerink Partners Global Healthcare Conference2025-03-11T11:20:00
TD Cowen 45th Annual Health Care Conference2025-03-04T11:10:00
Cullinan Therapeutics Inc Fourth Quarter Earnings Results for 20242025-02-27T00:00:00
Cullinan Therapeutics Inc Annual Report for 20242025-02-27T00:00:00
Guggenheim Securities SMID Cap Biotech Conference2025-02-05T09:30:00
Cullinan Therapeutics Inc Stifel Healthcare Conference 20242024-11-19T13:50:00
Cullinan Therapeutics Inc Third Quarter Earnings Results for 20242024-11-07T00:00:00
2024 Cantor Global Healthcare Conference2024-09-19T10:20:00
Morgan Stanley 22nd Annual Global Healthcare Conference2024-09-05T16:05:00
Cullinan Therapeutics Inc Second Quarter Earnings Results for 20242024-08-08T00:00:00
Cullinan Therapeutics Inc Annual General Meeting for 20242024-06-26T10:00:00
Cullinan Therapeutics will present the CLN-619 data shared at the 2024 ASCO Annual Meeting,2024-06-01T18:30:00
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit2024-05-29T11:30:00
Cullinan Therapeutics Inc First Quarter Earnings Results for 20242024-05-15T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.